Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,207Revenue $M2.6Net Margin (%)0Z-Score77.8
Enterprise Value $M1,081EPS $-0.6Operating Margin %0F-Score3
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yY
Price/Book10.210-y EBITDA Growth Rate %0Quick Ratio11.7Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %-13.0Current Ratio11.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-40.4Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-43.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M100ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with ACHN

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ACHNJohn Burbank 2014-12-31 Buy 0.01%$9.76 - $15.49
($12.28)
$ 12.351%New holding, 36104 sh.36,104
ACHNJean-Marie Eveillard 2014-03-31 Sold Out -0.01%$3.08 - $4.2
($3.5)
$ 12.35253%Sold Out0
ACHNJean-Marie Eveillard 2013-12-31 Buy 0.01%$2.43 - $3.46
($2.9)
$ 12.35326%New holding, 600000 sh.600,000
ACHNJohn Burbank 2012-12-31 Sold Out -0.24%$7.2 - $11.1
($8.86)
$ 12.3539%Sold Out0
ACHNJohn Burbank 2012-09-30 Buy 0.24%$5.61 - $10.41
($7.06)
$ 12.3575%New holding, 500000 sh.500,000
ACHNGeorge Soros 2012-06-30 Sold Out -0.04%$5.94 - $10.95
($7.34)
$ 12.3568%Sold Out0
ACHNGeorge Soros 2012-03-31 Reduce-0.09%$7.71 - $12.375
($9.57)
$ 12.3529%Reduce -50%250,000
ACHNGeorge Soros 2011-12-31 Add0.16%$4.01 - $8
($6.15)
$ 12.35101%Add 2132.14%500,000
ACHNGeorge Soros 2011-09-30 Buy $4.63 - $8.31
($6.37)
$ 12.3594%New holding, 22400 sh.22,400
ACHNDavid Swensen 2007-12-31 Sold Out -0.06%$4.29 - $5.46
($4.9)
$ 12.35152%Sold Out0
ACHNDavid Swensen 2007-06-30 Buy 0.07%$5.02 - $6.16
($5.6)
$ 12.35120%New holding, 39955 sh.39,955
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ACHN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ACHN John Burbank 2014-12-3136,1040.040.01New Buy
ACHN - CALLJohn Burbank 2014-12-31207,0000.210.07
Premium Most recent portfolio changes are included for Premium Members only!


ACHN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Fenton Mary KayEVP and CFO 2015-01-23Sell13,125$16-22.38view
Deshpande MilindPresident and CEO 2015-01-21Sell100,000$15-17.2view
RA CAPITAL MANAGEMENT, LLC 2014-09-30Sell1,332,014$10.221.76view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-26Sell2,372,915$11.1711.19view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-23Sell2,595,071$11.2910.01view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-11Sell1,704,362$20356.3-99.94view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-11Sell1,704,362$12.45-0.24view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-02Sell835,293$11.636.79view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-08-27Sell2,711,352$11.339.62view
Truitt JosephEVP, Chief Commercial Officer 2014-08-25Sell25,000$10.8214.79view

Press Releases about ACHN :

    Quarterly/Annual Reports about ACHN:

    News about ACHN:

    Articles On GuruFocus.com
    Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
    Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 
    Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
    Top 4 Insider Buys of Last Week Jun 10 2013 
    comment on ACHN Mar 15 2013 
    comment on ACHN Mar 09 2013 
    Achillion Will Surge If New Drug Is Successful Apr 21 2012 
    Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 23 2012 
    Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 
    Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 27 2010 

    More From Other Websites
    Biotech Making A Comeback - Here Is One Stock to Watch Feb 26 2015
    Achillion Pharmaceuticals Announces Closing of Public Offering of Common Stock Feb 18 2015
    Achillion Pharmaceuticals Announces Closing of Public Offering of Common Stock Feb 18 2015
    Emergent BioSolutions Reports Positive Data on BioThrax - Analyst Blog Feb 16 2015
    Acorda Beats Q4 Earnings Estimates; Ampyra Sales Grow - Analyst Blog Feb 13 2015
    Ironwood Pharmaceuticals Cuts Loss on Higher Revenues - Analyst Blog Feb 13 2015
    AbbVie Seeks Japanese Approval for HCV Cocktail Treatment - Analyst Blog Feb 12 2015
    Hospira Beats on Q4 Earnings, Set to Be Acquired by Pfizer - Analyst Blog Feb 12 2015
    The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead, AbbVie, Regeneron and Alkermes... Feb 12 2015
    Achillion Pharmaceuticals Announces Pricing of Public Offering of Common Stock Feb 12 2015
    Achillion Pharmaceuticals Announces Pricing of Public Offering of Common Stock Feb 11 2015
    Celgene Up on Abraxane Getting Positive Recommendation - Analyst Blog Feb 11 2015
    Gilead Sciences Shares Rise Amid Insider Buy, Conference Presentation Broadcast - Stocks in the News Feb 11 2015
    Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates -... Feb 11 2015
    Zoetis Beats on Q4 Earnings, Provides In-Line 2015 Outlook - Analyst Blog Feb 11 2015
    Achillion: Hep C Drug Discounting May Hurt Our Market Value, Stock Price Feb 11 2015
    BUZZ-U.S. STOCKS ON THE MOVE-Genworth, Oncolytics, Bellatrix, Chico's Fas Feb 11 2015
    JMP Securities Covers Mostly Good News From Pharma Pending More Visibility Feb 11 2015
    ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 11 2015
    Achillion Pharmaceuticals Announces Proposed Public Offering of Common Stock Feb 10 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK